Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Patients eligible for treatment with simeprevir in a French center.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Sept 2014

Morel Virginie, Duverlie Gilles, Brochot Etienne

Abstract excerpt

BACKGROUND: Simeprevir (Olysio(®)), a second-wave protease inhibitor recently approved for the treatment of chronic hepatitis C, is not indicated in patients with genotype 1a strain harboring the Q80K protease mutation. Phase 2 and 3 studies on this molecule mainly focused on North American patients and the prevalence of Q80K is particularly high in the USA (around 50%). The prevalence of this mutation in other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Sulfonamides
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to France

Share to Hepatitis C, Chronic

Share to Heterocyclic Compounds, 3-Ring

Share to Mutant Proteins

Share to Simeprevir

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 25027573
DOI: 10.1016/j.jcv.2014.06.023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patients eligible for treatment with simeprevir in a French center.PMID 25027573Read ↗

Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: implication for simeprevir usage.Semantic proximity Read ↗

[Determination of the naturally occurring Q80K mutation in the HCV NS3 protease gene].Semantic proximity Read ↗

Genotypic analysis of HCV 1a by sequencing of the NS3 proteasic region in simeprevir therapy candidates.Semantic proximity Read ↗

Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region.Semantic proximity Read ↗

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studiesSemantic proximity Read ↗

Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients.Semantic proximity Read ↗

Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience.Semantic proximity Read ↗

Simeprevir and sofosbuvir for treatment of hepatitis C infection.Semantic proximity Read ↗

Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort.Semantic proximity Read ↗

Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK.Semantic proximity Read ↗

New real-time-PCR method to identify single point mutations in hepatitis C virus.Semantic proximity Read ↗

In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.